|
JPS5836308B2
(ja)
|
1977-02-10 |
1983-08-08 |
大塚製薬株式会社 |
抗体の製造方法
|
|
US4206199A
(en)
|
1977-07-22 |
1980-06-03 |
Takeda Chemical Industries, Ltd. |
Novel glucagon fragment and its derivatives
|
|
JPS56163456A
(en)
|
1980-05-21 |
1981-12-16 |
Otsuka Pharmaceut Co Ltd |
Preparation of antigen
|
|
US4423034A
(en)
|
1980-10-16 |
1983-12-27 |
Toyo Jozo Kabushiki Kaisha |
Process for the preparation of antibodies
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
EP0658200B1
(en)
|
1992-08-28 |
2004-12-22 |
Novo Nordisk A/S |
Glucagon receptors
|
|
JP2729159B2
(ja)
|
1994-10-31 |
1998-03-18 |
日清製粉株式会社 |
ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
CA2547785A1
(en)
|
2003-12-19 |
2005-07-21 |
Merck & Co., Inc. |
Cyclic guanidines, compositions containing such compounds and methods of use
|
|
DE602005006806D1
(de)
|
2004-06-04 |
2008-06-26 |
Merck & Co Inc |
Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
|
|
DE102004028862A1
(de)
|
2004-06-15 |
2005-12-29 |
Merck Patent Gmbh |
3-Aminoindazole
|
|
AU2005272043B2
(en)
|
2004-07-07 |
2010-07-29 |
Merck Sharp & Dohme Corp. |
Pyrazole amide derivatives, compositions containing such compounds and methods of use
|
|
US7625938B2
(en)
|
2004-07-22 |
2009-12-01 |
Merck & Co., Inc. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
|
SI1856090T1
(sl)
|
2005-02-11 |
2010-02-26 |
Lilly Co Eli |
Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
|
|
US8318760B2
(en)
|
2005-03-21 |
2012-11-27 |
Merck Sharp & Dohme Corp. |
Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
|
|
US7803951B2
(en)
|
2005-03-30 |
2010-09-28 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
AR056574A1
(es)
|
2005-10-19 |
2007-10-10 |
Merck & Co Inc |
Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
|
|
CA2649751A1
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compound/glucagon antibody compositions
|
|
CL2007002668A1
(es)
|
2006-09-20 |
2008-05-09 |
Amgen Inc |
Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
|
|
TW200821284A
(en)
|
2006-10-03 |
2008-05-16 |
Merck & Co Inc |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
KR20190126460A
(ko)
|
2007-02-09 |
2019-11-11 |
메타베이시스 테라퓨틱스, 인크. |
글루카곤 수용체의 길항제
|
|
CL2009000586A1
(es)
|
2008-03-27 |
2010-06-04 |
Lilly Co Eli |
Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
|
|
EP2291358B1
(en)
|
2008-05-16 |
2018-03-28 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonists, compositions, and methods for their use
|
|
EP2346830B1
(en)
|
2008-09-15 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
WO2010071750A1
(en)
|
2008-12-19 |
2010-06-24 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds
|
|
US20110281795A1
(en)
|
2009-01-28 |
2011-11-17 |
Songnian Lin |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
US8324384B2
(en)
|
2009-02-12 |
2012-12-04 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
US8809579B2
(en)
|
2009-02-13 |
2014-08-19 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
US8318667B2
(en)
|
2009-02-25 |
2012-11-27 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
|
JP2012188352A
(ja)
|
2009-07-13 |
2012-10-04 |
Dainippon Sumitomo Pharma Co Ltd |
３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
|
|
FR2959129B1
(fr)
*
|
2010-04-21 |
2013-02-01 |
Lucane Pharma |
Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
DK2760479T3
(en)
|
2011-09-30 |
2017-07-17 |
Horizon Therapeutics Llc |
Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
|
|
US9453073B2
(en)
|
2011-12-02 |
2016-09-27 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
|
KR20170062466A
(ko)
|
2014-09-16 |
2017-06-07 |
리제너론 파마슈티칼스 인코포레이티드 |
항-글루카곤 항체 및 그것의 사용
|